Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma
Michael Rink(Marienkrankenhaus Hamburg), Shahrokh F. Shariat(Al-Ahliyya Amman University), Felix K.‐H. Chun(Universität Hamburg), Wassim Kassouf(McGill University Health Centre), Mesut Remzi(Landesklinikum Korneuburg), Yair Lotan(The University of Texas Southwestern Medical Center), Kanishka Sircar(McGill University), Guru Sonpavde(Dana-Farber Cancer Institute), Douglas S. Scherr(NewYork–Presbyterian Hospital), Brian D. Robinson(Cornell University), Maxine Sun(Université de Montréal), Karim Bensalah(Université de Rennes), Wareef Kabbani(The University of Texas Southwestern Medical Center), Casey K. Ng(NewYork–Presbyterian Hospital), David A. Green(NewYork–Presbyterian Hospital), Evi Comploj(Ospedale di Bolzano), Andrea Haitel(University of Vienna), Vitaly Margulis(The University of Texas MD Anderson Cancer Center), Jens Hansen(Icahn School of Medicine at Mount Sinai), Pierre I. Karakiewicz(Université de Montréal), Nathalie Rioux‐Leclercq(Université de Rennes), Armin Pycha(Ospedale di Bolzano), Charles C. Guo(The University of Texas MD Anderson Cancer Center), Jay D. Raman(Cornell University), Eiji Kikuchi(Keio University)
Cited by 142
Related Papers
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
|Journal of Clinical Oncology|2011|686
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|Cancer Cell|2021|624